Time from Solid Organ Transplant (SOT) Until Start Date of the Symptomatic or Asymptomatic Index Episode [Time Frame: From SOT up to start date of the index episode (Up to 7 years 3 months)]
Percentage of Participants who are Asymptomatic and Symptomatic at the Index and Recurrent Episodes [Time Frame: Up to 7 years 3 months]
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at the Index Episode and for Recurrent Episodes [Time Frame: Up to 7 years 3 months]
Time From Start of Index Episode to CMV Viremia Clearance as Defined by Site Investigator [Time Frame: From start of index episode to CMV viremia clearance (Up to 7 years 3 months)]
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at Week 8 After Index Date [Time Frame: At Week 8 after index date]
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at Week 20 After Index Date [Time Frame: At Week 20 after index date]
Percentage of Participants With CMV Viremia Clearance as Defined by Site Investigator at 1-year After Index Date [Time Frame: At 1-year after index date]
Percentage of Participants With Non-detectable CMV During the Index Episode Prior to and After the Index Date [Time Frame: Up to 7 years 3 months]
Percentage of Participants With Evidence of Non-detectable CMV at Week 8 After Index Date [Time Frame: At Week 8 after index date]
Percentage of Participants With Evidence of Non-detectable CMV at Week 20 After Index Date [Time Frame: At Week 20 after index date]
Percentage of Participants With Evidence of Non-detectable CMV at 1-year After Index Date [Time Frame: At 1-year after index date]
Time From Treatment Initiation to CMV Viremia Clearance as Defined by Site Investigator at the Index Episode [Time Frame: From Treatment Initiation to CMV Viremia Clearance (Up to 7 years 3 months)]
Time From Treatment Initiation Until Evidence of Non-detectable CMV at the Index Episode [Time Frame: Time from treatment initiation until evidence of non-detectable CMV (Up to 7 years 3 months)]
Time from Start of Index Episode to First Symptomatic CMV Diagnosis [Time Frame: From start of index episode to first symptomatic CMV diagnosis (Up to 7 years 3 months)]
Time From Stop Date of the Index Episode to First Recurrent Asymptomatic and Symptomatic CMV Viremia [Time Frame: From stop date of the index episode to first recurrent asymptomatic and symptomatic CMV viremia (Up to 7 years 3 months)]
Percentage of Participants With Anti-CMV Treatment-related Myelosuppression and Nephrotoxicity [Time Frame: Up to 7 years 3 months]
Percentage of Participants With Organ Rejection From SOT [Time Frame: Up to 7 years 3 months]
Percentage of Participants With Graft Loss From SOT and the Index Date [Time Frame: Up to 7 years 3 months]
Percentage of Participants who Died due to any Cause From SOT and Index Date [Time Frame: Up to 7 years 3 months]
Percentage of Participants who Died due to CMV Infection From SOT and Index Date [Time Frame: Up to 7 years 3 months]
Number of Genetic Mutations Conferring Anti-CMV Resistance From SOT and Index Date [Time Frame: Up to 7 years 3 months]
Percentage of Participants With a Genetic Mutation Conferring Anti-CMV Resistance From SOT at the Index Date [Time Frame: Up to 7 years 3 months]